ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	6/11/2016 8:24:47 PM
	of 4474

Pona posters from EHA 2016 available at Incyte (fka Ariad)... ariadnordics.eu Some highlights. From PACE 4-year data: "Exposure-adjusted incidence of AOEs has not increased over time...Maintenance of response was high, in particular, for patients at 15 mg/d." From PACE vs. Real World (US) "As expected, the duration of therapy in real-world patients was shorter than in PACE patients, likely owing to real-world noncompliance and availability of alternative therapies. Nonetheless, the majority of real-world ponatinib patients across all lines of therapy remained on therapy for >1.5 years, as compared with >2 years for PACE patients...Third-line clinical trial data for bosutinib (TKI with an overlapping indication) report median duration on bosutinib treatment of 8.3 months (range, 0.2–51.8 months)5; in comparison, 64% of PACE 3rd-line patients remained on therapy at 24 months (median not reached) and 59% of real-world ponatinib patients remained on therapy at 18 months (median not reached)."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next